ASCO 2017 Renal Cancer - Results from #20

Viewing 21-40 of 44 articles

ASCO 2017: Prognostic role of circulating tumor cells in metastatic renal cell carcinoma

ASCO 2017: Microvessel density as a prognostic marker in high-risk renal cell carcinoma

ASCO 2017: Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma and brain metastases: Preliminary results from the GETUG-AFU 26 (Nivoren) study

ASCO 2017: Safety and efficacy of docetaxel + b-701, a selective inhibitor of FGFR3, in subjects with advanced or metastatic urothelial carcinoma

ASCO 2017: Exploring Novel Dosing and Combination Strategies in Metastatic Renal Cell Carcinoma

ASCO 2017: Discovery and prevalence of cancer-susceptibility germline mutations in patients with advanced renal cell carcinoma

ASCO 2017: Integrated biomarker analysis for 412 renal cell cancer patients treated on the phase 3 COMPARZ trial

ASCO 2017: Association of on-treatment plasma HGF levels with overall survival in patients with advanced renal cell carcinoma treated with interferon alpha +/- bevacizumab (BEV): Results from CALGB 90206 (Alliance)

ASCO 2017: Incidence of T3a upstaging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis

ASCO 2017: Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis

ASCO 2017: Impact of geographic region on overall survival in patients with metastatic renal cell carcinoma: Results from a pooled clinical trials database

ASCO 2017: Effects of pazopanib and sunitinib dose modification on safety and efficacy in patients with metastatic renal cell carcinoma from COMPARZ

ASCO 2017: Long-term response and time to response to pazopanib and sunitinib in metastatic renal cell carcinoma: COMPARZ subanalysis

ASCO 2017: Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset

ASCO 2017: Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)

ASCO 2017: Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)

ASCO 2017: Safety and efficacy of nivolumab for metastatic renal cell carcinoma (mRCC): Real world data from an Italian expanded access program (EAP)

ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced RCC: Preliminary phase I/II results from ECHO-202/KEYNOTE-037

ASCO 2017: Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer

ASCO 2017: Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carcinoma

1
2
3